Henning K J, Delencastre H, Eagan J, Boone N, Brown A, Chung M, Wollner N, Armstrong D
Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Pediatr Infect Dis J. 1996 Oct;15(10):848-54. doi: 10.1097/00006454-199610000-00004.
To determine the duration of stool shedding and incidence of clinical infection among pediatric oncology patients colonized with vancomycin-resistant Enterococcus faecium (VRE) in our institution.
Stool cultures were obtained from all patients admitted from May 15 to August 2, 1994. Patients were followed for evidence of clinical VRE infection and surveillance stool results through August 15, 1995. Genetic relatedness of stool-clinical isolate pairs and serial stool samples was evaluated using pulsed field gel electrophoresis.
Twenty-three (32%) of 73 screened patients were colonized with VRE. Eight (35%) of the colonized patients cleared VRE from stool; 10 (43%) were persistent carriers, excreting organisms for 19 to 331 days (median, 112 days); and 5 patients had an insufficient number of stools to determine length of carriage. Persistent carriers had a median of 6 hospital readmissions; 8 of 10 were positive at first or second readmission Clinical VRE infection developed in 6 of 73 patients (annual incidence, 8.2%). Clinical cases had more days of neutropenia between colonization and infection than colonized patients during a comparable follow-up (49 vs. 16 days, P = 0.04). Five of 6 stool-clinical isolate pairs were identical by pulsed field gel electrophoresis. Serial stools from 6 of 7 patients (collected 20 to 343 days apart) were identical by pulsed field gel electrophoresis.
Persistent gastrointestinal colonization with VRE is common among pediatric oncology patients. Carriage of the same VRE clone for up to 1 year was demonstrated. In the majority of cases invasive and colonizing isolates were identical by DNA fingerprinting techniques, suggesting that the colonizing VRE was the source of infection. Intermittent excretion of organisms in stool makes vigilant tracking and immediate isolation of such patients crucial to control efforts. Prolonged neutropenia may increase the risk of developing clinical infection among VRE-colonized patients.
确定我院儿科肿瘤患者中耐万古霉素屎肠球菌(VRE)定植后的粪便排菌持续时间及临床感染发生率。
对1994年5月15日至8月2日入院的所有患者进行粪便培养。对患者进行随访,观察临床VRE感染证据及截至1995年8月15日的监测粪便结果。采用脉冲场凝胶电泳评估粪便-临床分离株对及系列粪便样本的基因相关性。
73例筛查患者中有23例(32%)VRE定植。8例(35%)定植患者粪便中VRE清除;10例(43%)为持续携带者,排菌19至331天(中位数112天);5例患者粪便样本数量不足,无法确定携带时间。持续携带者再次入院次数中位数为6次;10例中有8例在首次或第二次再次入院时呈阳性。73例患者中有6例发生临床VRE感染(年发生率8.2%)。在可比的随访期间,临床病例在定植至感染期间的中性粒细胞减少天数多于定植患者(49天对16天,P = 0.04)。6对粪便-临床分离株中有5对经脉冲场凝胶电泳鉴定相同。7例患者中有6例的系列粪便(采集间隔20至343天)经脉冲场凝胶电泳鉴定相同。
儿科肿瘤患者中VRE持续胃肠道定植很常见。已证明同一VRE克隆可携带长达1年。在大多数情况下,通过DNA指纹技术,侵袭性和定植性分离株相同,提示定植的VRE是感染源。粪便中生物体的间歇性排泄使得对此类患者进行密切追踪和立即隔离对于防控工作至关重要。长期中性粒细胞减少可能增加VRE定植患者发生临床感染的风险。